Skip to main content
What types of page to search?

Popular pages: Undergraduate Postgraduate PhD Accommodation Research International students

Alternatively use our A-Z index.

2020

Outputs from 2020

Cell Membrane Transporters Facilitate the Accumulation of Hepatocellular Flucloxacillin Protein Adducts: Implication in Flucloxacillin-Induced Liver Injury

  • Waddington JC, Ali SE, Penman SL, Whitaker P, Hamlett J, Chadwick A, Naisbitt DJ, Park BK, Meng X. (2020). Chem Res Toxicol. 2020 Nov 10.

The utility of a differentiated preclinical liver model, HepaRG cells, in investigating delayed toxicity via inhibition of mitochondrial-replication induced by fialuridine

  • Jolly, C. E., Douglas, O., Kamalian, L., Jenkins, R. E., Beckett, A. J., Penman, S. L., Williams, D. P., Monshouwer, M., Simic, D., Snoeys, J., Park, B. K., and Chadwick, A. E. (2020) Toxicology and applied pharmacology.

Identification of flucloxacillin-haptenated HLA-B*57:01 ligands: evidence of antigen processing and presentation

  • Waddington JC, Meng M, Illing PT, Tailor A, Jenkins R, Purcell AW, Naisbitt DJ, Park BK. (2020) Toxicol Sci.

HLA DRB1*15:01-DQB1*06:02-restricted human CD4+ T-cells are selectively activated with amoxicillin-peptide adducts

  • Tailor A, Meng X, Farrell J, Waddington J, Daly A, Pirmohamed M, Dear G, Park BK, Naisbitt DJ. (2020) Toxicol Sci.

Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4 + T lymphocytes

  • Roehmel JF, Ogese MO, Rohrbach A, Mall MA, Naisbitt DJ. (2020) J Allergy Clin Immunol.

Biopsy pathology and immunohistochemistry of a case of immune-mediated drug-induced liver injury with Atabecestat

  • De Jonghe S, Weinstock D, Aligo J, Washington K, Naisbitt D. (2020) Hepatology.

Characterization of Clozapine-Responsive Human T Cells

  • Ogese MO, Lister A, Jenkins RE, Meng X, Alfirevic A, Douglas L, Mcloughlin R, Silva E, Park BK, Pirmohamed M, Naisbitt DJ. (2020) J Immunol.

Immune dysregulation increases the incidence of delayed-type drug hypersensitivity reactions

  • Naisbitt DJ, Olsson-Brown A, Gibson A, Meng X, Ogese MO, Tailor A, Thomson P. Allergy. 2020 Apr.

Shedding light on drug-induced liver injury: activation of T-cells from drug naive human donors with tolvaptan and a hydroxybutyric acid metabolite

  • Hammond S, Gibson A, Roth S Naisbitt DJ. (2020) Toxicol Sci.

Tolvaptan and tolvaptan metabolite-responsive T cells in patients with drug-induced liver injury

  • Hammond S, Gibson A, Roth S Naisbitt DJ. (2020) Chem Res Toxicol.

Drug-specific T-cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat

  • Thomson P, Kafu L, Meng X, Snoeys J, De Bondt A, De Maeyer D, Wils H, Leclercq L, Vinken P, Naisbitt DJ. (2020) Allergy. Nov 4.

HLA Class II-restricted CD8+ T cells contribute to the promiscuous immune response in dapsone hypersensitive patients

  • Zhao Q, Almutairi M, Tailor A, Lister A , Harper N, Line J, Meng X, Pratoomwun J, Sukasem C, Sun Y, Sun L, Ogese MO, MacEwan DJ, Pirmohamed M, Liu J, Ostrov DA, Liu H, Zhang F, Naisbitt DJ. (2020) J Invest Dermatol.

Managing the Challenge of Drug Induced Liver Injury: A roadmap for the development and deployment of preclinical predictive models

  • Weaver RW, Blomme EA, Chadwick AE, Copple IM, Gerets HJJ, Goldring CE, Guillouzo A, Hewitt PG, Ingelman-Sundberg M, Jensen KG, Juhila S, Klingmüller U, Labbe G, Liguori MJ, Lovatt CA, Morgan P, Naisbitt DJ, Pieters RHH, Snoeys J, van de Water B, Williams DP, Park BK. (2020) Nat Rev Drug Discov.

Characterization of amoxicillin/clavulanic acid specific T-cell clones from patients with immediate drug hypersensitivity

  • Ariza A, Fernández R, Meng X, Salas M, Ogese MO, Tailor A, Bogas G, Torres MJ, Naisbitt DJ. (2020) Allergy.

Development of an Improved T-cell Assay to Assess the Intrinsic Immunogenicity of Haptenic Compounds

  • Ogese MO, Watkinson J, Lister A, Faulkner L, Gibson A, Hillegas A, Sakatis MZ, Park BK, Naisbitt DJ. (2020) Toxicol Sci.

Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA-B*57:01 binding and T-cell activation

  • Thomson PJ, Illing PT, Farrell J, Alhaidari M, Berry N, O'Neill PM, Purcell AW, Park KB, Naisbitt DJ. (2020) Allergy.

Current perspective of the etiopathogenesis of delayed-type, and T-cell-mediated drug-related skin diseases

  • Vocanson M, Naisbitt DJ, Nicolas JF. J Allergy Clin Immunol. 2020 Apr.

Drug- and drug-metabolite-specific activation of T-cells from hypersensitive patients expressing HLA-risk alleles.

  • Zhao Q, Alhilali K, Alzahrani A, Almutairi M, Amjad J, Liu H, Sun Y, Sun L, Zhang H, Meng X, Gibson A, Ogese MO, Park BK, Liu J, Ostrov D, Zhang F, Naisbitt DJ. (2019) Allergy

T-cell activation by low molecular weight drugs and factors that influence susceptibility to drug hypersensitivity

  • Hammond S, Thomson PJ, Ogese MO, Naisbitt DJ. (2020) Chem Res Toxicol.

Definition of Haptens Derived from Sulfamethoxazole: In Vitro and in Vivo

  • Tailor A, Waddington JC, Hamlett J, Maggs J, Kafu L, Farrell J, Dear GJ, Whitaker P, Naisbitt DJ, Park K, Meng X. (2019) Chem Res Toxicol.

Exosomal transport of hepatocyte-derived drug-modified proteins to the immune system

  • Ogese MO, Jenkins RE, Meng X, Faulkner L, Enyindah BO, Schofield A, Diaz-Nieto R, Ressel L, Eagle GL, Kitteringham NR, Goldring GE, Park BK, Naisbitt DJ, Betts C. (2020) Hepatology.